{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:4355"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:4355","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The immune response to cytomegalovirus and Epstein-Barr virus in systemic lupus erythematosus","abstract":"Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology. Both genetic and environmental factors are known to contribute to disease development. Pathogenesis involves the production of autoantibodies, and the formation of immune complexes, leading to inflammation and destruction of autologous tissue. SLE is a heterogeneous disease both longitudinally and between affected individuals, and is characterised by periods of exacerbation, known as flares, and periods of remission. The ubiquitous human herpes viruses, cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) have been associated with disease by a variety of mechanisms. Data compiled here suggests SLE patients have elevated IgG responses to HCMV and EBV, but unlike healthy controls these responses do not accumulate with age. No association has been found between the carriage of these viruses, or the magnitude of response against these viruses, and any clinical measurements of disease activity. EBV load is 5.4 times higher in SLE patients than controls. Azathioprine treatment is associated with a 4.4 fold rise in EBV load, no other drugs show associations with EBV load. Among SLE patients EBV load is inversely correlated with CD8+ T-cell IFN\\(\\gamma\\) responses, suggesting impaired T-cell responses are the cause of elevated load. HCMV seropositivity is associated with a 7-year delay in development of disease among SLE patients, and a reduction in plasma IFN\\(\\alpha\\) concentration.","abstract_html":"Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology. Both genetic and environmental factors are known to contribute to disease development. Pathogenesis involves the production of autoantibodies, and the formation of immune complexes, leading to inflammation and destruction of autologous tissue. SLE is a heterogeneous disease both longitudinally and between affected individuals, and is characterised by periods of exacerbation, known as flares, and periods of remission. The ubiquitous human herpes viruses, cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) have been associated with disease by a variety of mechanisms. Data compiled here suggests SLE patients have elevated IgG responses to HCMV and EBV, but unlike healthy controls these responses do not accumulate with age. No association has been found between the carriage of these viruses, or the magnitude of response against these viruses, and any clinical measurements of disease activity. EBV load is 5.4 times higher in SLE patients than controls. Azathioprine treatment is associated with a 4.4 fold rise in EBV load, no other drugs show associations with EBV load. Among SLE patients EBV load is inversely correlated with CD8+ T-cell IFN<span class=\"etd-inline-math\">&gamma;</span> responses, suggesting impaired T-cell responses are the cause of elevated load. HCMV seropositivity is associated with a 7-year delay in development of disease among SLE patients, and a reduction in plasma IFN<span class=\"etd-inline-math\">&alpha;</span> concentration.","abstract_has_math":true,"creators":["Perks, Emma Laura"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-07","date_published":"2013-07","updated_at":"2026-11-19T09:27:39Z","subjects":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/4355/1/Perks13PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A4355","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Perks, Emma Laura"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013-07"]},{"key":"dc:date.issued","label":"Date","values":["2013-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Cancer Studies"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/4355/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/4355/1/Perks13PhD.pdf","http://etheses.bham.ac.uk//id/eprint/4355/2/Decl_IS_Perks13PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology. Both genetic and environmental factors are known to contribute to disease development. Pathogenesis involves the production of autoantibodies, and the formation of immune complexes, leading to inflammation and destruction of autologous tissue. SLE is a heterogeneous disease both longitudinally and between affected individuals, and is characterised by periods of exacerbation, known as flares, and periods of remission. The ubiquitous human herpes viruses, cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) have been associated with disease by a variety of mechanisms. Data compiled here suggests SLE patients have elevated IgG responses to HCMV and EBV, but unlike healthy controls these responses do not accumulate with age. No association has been found between the carriage of these viruses, or the magnitude of response against these viruses, and any clinical measurements of disease activity. EBV load is 5.4 times higher in SLE patients than controls. Azathioprine treatment is associated with a 4.4 fold rise in EBV load, no other drugs show associations with EBV load. Among SLE patients EBV load is inversely correlated with CD8+ T-cell IFN\\(\\gamma\\) responses, suggesting impaired T-cell responses are the cause of elevated load. HCMV seropositivity is associated with a 7-year delay in development of disease among SLE patients, and a reduction in plasma IFN\\(\\alpha\\) concentration."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The immune response to cytomegalovirus and Epstein-Barr virus in systemic lupus erythematosus"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Perks, Emma Laura"],"dc:date":["2013-07"],"dc:date.issued":["2013-07"],"dc:description.abstract":["Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology. Both genetic and environmental factors are known to contribute to disease development. Pathogenesis involves the production of autoantibodies, and the formation of immune complexes, leading to inflammation and destruction of autologous tissue. SLE is a heterogeneous disease both longitudinally and between affected individuals, and is characterised by periods of exacerbation, known as flares, and periods of remission. The ubiquitous human herpes viruses, cytomegalovirus (HCMV), and Epstein-Barr virus (EBV) have been associated with disease by a variety of mechanisms. Data compiled here suggests SLE patients have elevated IgG responses to HCMV and EBV, but unlike healthy controls these responses do not accumulate with age. No association has been found between the carriage of these viruses, or the magnitude of response against these viruses, and any clinical measurements of disease activity. EBV load is 5.4 times higher in SLE patients than controls. Azathioprine treatment is associated with a 4.4 fold rise in EBV load, no other drugs show associations with EBV load. Among SLE patients EBV load is inversely correlated with CD8+ T-cell IFN\\(\\gamma\\) responses, suggesting impaired T-cell responses are the cause of elevated load. HCMV seropositivity is associated with a 7-year delay in development of disease among SLE patients, and a reduction in plasma IFN\\(\\alpha\\) concentration."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/4355/1/Perks13PhD.pdf","http://etheses.bham.ac.uk//id/eprint/4355/2/Decl_IS_Perks13PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Cancer Studies"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/4355/"],"dc:subject":["RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The immune response to cytomegalovirus and Epstein-Barr virus in systemic lupus erythematosus"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:39Z"}